ALFA Finder| Revenue growth | -2% CAGR over FY23-26. |
|---|---|
| Margins | Transition costs in FY27; long-term margin uplift via procurement optimization. |
| Demand visibility | Strong legacy brand loyalty; 'Minipress' has ~63% value share. |
| Management confidence | High: focus on re-establishing in-house promotion to unlock value. |
Growth
FY26 revenue at ₹354 Cr (-2% CAGR FY23-26). PAT at ₹93 Cr (-3% CAGR).
Outlook
Targets above-market growth via a dedicated 900+ field force and aggressive M&A strategy for chronic therapies.
Risks
One-time transition costs and partnership termination fees expected in Q2-Q4 FY27 to impact margins.
Investor Presentation filed with BSE, NSE: NOVARTIND. Summary written with AI assistance from the document.
Novartis India Ltd: key numbers
- Share price
- ₹1,562.55
- Market cap
- ₹5,064 Cr
- Revenue (annual)
- ₹354.3 Cr
- Net profit (annual)
- ₹93.18 Cr
- P/E (TTM)
- -1269.1×Sector 43.8×
- Promoter holding
- 70.68%+0.00% QoQ
- FII holding
- 1.21%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Novartis India Ltd
All →Evonile Pharma Fund Raise of ₹900 Cr
Evonile Pharma's board approved a partly paid rights issue of up to Rs 900 Crore. A committee will set the issue price, record date and entitlement.
- Value
- ₹900.0 Cr
Evonile Pharma Capital Structure Change
Evonile Pharma's Rights Issue Committee fixed November 11, 2026 as record date for a partly paid rights issue of 1,02,87,832 shares at Rs.860 each. Issue size is Rs.8,847.54 Million, with issue opening November 19, 2026.
- Value
- ₹884.8 Cr
- Execution
- Issue opening 19 Nov 2026 to closing 3 Dec 2026; listing on or about 9 Dec 2026
Evonile Pharma Earnings Call Transcript: Key Takeaways
Q2 FY27 revenue ₹56.1 cr (-38% YoY) and PAT loss ₹77.5 cr, including ₹68 cr exceptional items. H1 revenue ₹159.9 cr (-10%). Transitioning to an independent branded pharma model; Minipress XL acquired.
Evonile Pharma Results Update
Evonile Pharma reported Q2 FY27 revenue of ₹56.1 crore and an EBITDA loss of ₹31.8 crore. H1 FY27 profit after tax was a loss of ₹45.3 crore.
Evonile Pharma Investor Presentation: Key Takeaways
Q2 FY27 revenue fell 38% YoY to ₹56.1 cr, with a ₹77.5 cr net loss including ₹68 cr exceptional items. Transition from single-customer model to independent distribution continues.
Evonile Pharma Q2 FY27 Results: Net Loss of ₹77.5 Cr
Evonile Pharma posted a ₹775.4 million quarterly loss for September 2026 versus profit a quarter earlier. Exceptional items of ₹682.6 million drove the half-year pre-tax loss.
- Key figure
- Net loss ₹77.5 Cr